Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phas... by van Ramshorst, Mette S, MD, van der Voort, Anna, MD, van Werkhoven, Erik D, MSc, Mandjes, Ingrid A, MSc, Kemper, Inge, MANP, Dezentjé, Vincent O, MD, Oving, Irma M, MD, Honkoop, Aafke H, MD, Tick, Lidwine W, MD, van de Wouw, Agnes J, MD, Mandigers, Caroline M, MD, van Warmerdam, Laurence J, MD, Wesseling, Jelle, Prof, Vrancken Peeters, Marie-Jeanne T, MD, Linn, Sabine C, Prof, Sonke, Gabe S, MD

Get full text

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis by Henricks, Linda M, PharmD, Lunenburg, Carin A T C, MSc, de Man, Femke M, MD, Meulendijks, Didier, PharmD, Frederix, Geert W J, PhD, Kienhuis, Emma, BSc, Creemers, Geert-Jan, MD, Baars, Arnold, MD, Dezentjé, Vincent O, MD, Imholz, Alexander L T, MD, Jeurissen, Frank J F, MD, Portielje, Johanna E A, Prof, Jansen, Rob L H, MD, Hamberg, Paul, MD, ten Tije, Albert J, MD, Droogendijk, Helga J, MD, Koopman, Miriam, Prof, Nieboer, Peter, MD, van de Poel, Marlène H W, MD, Mandigers, Caroline M P W, MD, Rosing, Hilde, PhD, Beijnen, Jos H, Prof, Werkhoven, Erik van, MSc, van Kuilenburg, André B P, PhD, van Schaik, Ron H N, PhD, Mathijssen, Ron H J, Prof, Swen, Jesse J, PharmD, Gelderblom, Hans, Prof, Cats, Annemieke, MD, Guchelaar, Henk-Jan, Prof, Schellens, Jan H M, Prof

Get full text